Raloxifene therapy does not affect uterine blood flow in postmenopausal women: a transvaginal Doppler study

Endometrial hysteroscopic and histological evaluation in menopausal women in continuous use of raloxifene

“…Such results must be considered due to the interface of use of raloxifene with the menopausal state of the patients concerned; that is, there may be two concurrent factors leading to decreased estrogen activity in the endometrium. Different clinical studies involving raloxifene (14,15) aimed to assess the endometrial effects of the drug in large populations. For instance, the endometrial thickness and the size of the uterus were evaluated by transvaginal ultrasound and, in a subgroup of patients, the histological pattern was assessed by endometrial biopsy.…”

Effects of raloxifene therapy on the anticoagulant system in postmenopausal women

“…Additional advantages of raloxifene use by postmenopausal women include its antagonist effects on the breast and uterus 5,7 . In another article we report that raloxifene treatment at the dose of 60 mg/day for 6 months did not induce significant changes in endometrial thickness, uterine volume or uterine artery perfusion 8 .…”

Association of Ovarian and Uterine Cancers With Postmenopausal Hormonal Treatments

“…53 Nevertheless, raloxifene has been associated with a very low incidence of spotting/bleeding compared with tibolone 54 a situation that is very rare in postmenopausal women under raloxifene treatment. 55 In 25 healthy postmenopausal women on 60 mg/d of raloxifene during 6 months of therapy there was no significant change in endometrial thickness or uterine artery blood flow, [56][57][58] and it seems to act as an endometrial antagonist. 59,60 The only exception is a case where there was an association between raloxifene and the development of a malignant mixed mesodermal tumor, a rare variant of uterine cancer, in a 64-year-old woman with a bicornuate uterus.…”